Fully integrated biosensing platform-integrating blood/plasma separation, digital microfluidics, and electrochemistry

全集成生物传感平台——集成血液/血浆分离、数字微流体和电化学

• 批准号: 570448-2021
• 负责人: Soleymani, Leyla
• 金额: $ 11.2万
• 依托单位: McMaster University
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=722687
• 关键词: Fully; integrated; biosensing; platform; integrating

Recently, there has been a great movement toward telemedicine and remote healthcare. Despite development of the digital infrastructure for remote consultation of patients with healthcare providers, there is a lack of bioanalytical technologies for at home use. These technologies analyze patient specimens for markers of health or disease. In the post-pandemic world of virtual consultations, there is a major opportunity for transformative bioanalytical technologies that can be used at the point-of-need. This is currently a 33-billion-dollar industry that is projected to experience double digit annual growths in the next five years.In this proposal, we will combine multiple innovative technologies, developed over decades of research at McMaster University and Verv Technologies, for the first time to solve the technological and scientific challenges involved in analyzing a drop of unprocessed blood for a panel of biomarkers at the point-of-need. McMaster University has developed a bio-barcode assay that uses DNA/antibody assemblies for specifically targeting biomarkers and releasing an electroactive DNA barcode for generating an electrical signal. This system is highly sensitive and specific and is amenable to analyzing multiple analytes at once. The assay currently works with undiluted plasma, requires long incubation steps, and is operated using a series of manual steps that is difficult to follow by a novice user. Verv technologies has developed a patented platform for assay automation that is designed to work directly with blood and small sample volumes to reduce assay time. Combining the two technologies, with support from this grant, is expected to overcome the major hurdles that have inhibited the translation of biosensors from the research lab to the market. The development of this unique technology in Canada, initially targeted to the monitoring of prostate cancer, will generate research and development and manufacturing jobs, and will positively contribute to Canada's medical technology landscape. Marketing such technology is critically important for delivering high quality healthcare in Canada and globally in a world moving to virtual care, and is expected to bring equity to the delivery of healthcare.

最近，远程医疗和远程医疗保健出现了巨大的发展。尽管开发了用于患者与医疗保健提供者远程咨询的数字基础设施，但仍缺乏适合家庭使用的生物分析技术。这些技术分析患者样本中的健康或疾病标志。在大流行后的虚拟咨询世界中，可在需要时使用的变革性生物分析技术存在重大机遇。目前这是一个价值 330 亿美元的行业，预计在未来五年内将实现两位数的年增长率。在这项提案中，我们将结合麦克马斯特大学和 Verv Technologies 经过数十年研究开发的多项创新技术，以实现首次解决了在需要时分析一滴未经处理的血液中的一组生物标记物所涉及的技术和科学挑战。麦克马斯特大学开发了一种生物条形码测定法，该测定法使用 DNA/抗体组合物专门针对生物标志物，并释放电活性 DNA 条形码以产生电信号。该系统具有高度灵敏性和特异性，能够同时分析多种分析物。该检测目前使用未稀释的血浆，需要较长的孵育步骤，并且使用一系列新手用户难以遵循的手动步骤进行操作。 Verv Technologies 开发了一个用于检测自动化的专利平台，该平台旨在直接处理血液和小体积样本，以减少检测时间。在这笔赠款的支持下，将这两种技术结合起来，预计将克服阻碍生物传感器从研究实验室向市场转化的主要障碍。这项独特技术在加拿大的开发最初旨在监测前列腺癌，将创造研发和制造就业机会，并将为加拿大的医疗技术格局做出积极贡献。在转向虚拟护理的世界中，营销此类技术对于在加拿大和全球范围内提供高质量的医疗保健至关重要，并且有望为医疗保健的提供带来公平。